NO20041685L - Fremgangsmate for behandling av hepatitt C-virusinfeksjon hos pasienter med manglende behandlingsrespons - Google Patents

Fremgangsmate for behandling av hepatitt C-virusinfeksjon hos pasienter med manglende behandlingsrespons

Info

Publication number
NO20041685L
NO20041685L NO20041685A NO20041685A NO20041685L NO 20041685 L NO20041685 L NO 20041685L NO 20041685 A NO20041685 A NO 20041685A NO 20041685 A NO20041685 A NO 20041685A NO 20041685 L NO20041685 L NO 20041685L
Authority
NO
Norway
Prior art keywords
treatment
hepatitis
patients
procedure
virus infection
Prior art date
Application number
NO20041685A
Other languages
English (en)
Inventor
Henry H Hsu
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of NO20041685L publication Critical patent/NO20041685L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20041685A 2001-09-28 2004-04-27 Fremgangsmate for behandling av hepatitt C-virusinfeksjon hos pasienter med manglende behandlingsrespons NO20041685L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32610001P 2001-09-28 2001-09-28
PCT/US2002/030006 WO2003028754A1 (en) 2001-09-28 2002-09-20 Method for treating hepatitis c virus infection in treatment failure patients

Publications (1)

Publication Number Publication Date
NO20041685L true NO20041685L (no) 2004-06-23

Family

ID=23270817

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041685A NO20041685L (no) 2001-09-28 2004-04-27 Fremgangsmate for behandling av hepatitt C-virusinfeksjon hos pasienter med manglende behandlingsrespons

Country Status (14)

Country Link
US (2) US20050031585A1 (no)
EP (1) EP1435997A4 (no)
JP (1) JP2005508926A (no)
KR (1) KR20040037191A (no)
CN (1) CN1561227A (no)
AR (1) AR036698A1 (no)
BR (1) BR0212928A (no)
CA (1) CA2461596A1 (no)
HU (1) HUP0401659A3 (no)
IL (1) IL160882A0 (no)
MX (1) MXPA04002915A (no)
NO (1) NO20041685L (no)
WO (1) WO2003028754A1 (no)
ZA (1) ZA200402231B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100316608A1 (en) * 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6127046A (en) * 1997-12-04 2000-10-03 Cummins Engine Company, Inc. Formation of a graphite-free surface in a ferrous material to produce an improved intermetallic bond

Also Published As

Publication number Publication date
KR20040037191A (ko) 2004-05-04
US20050031585A1 (en) 2005-02-10
AR036698A1 (es) 2004-09-29
EP1435997A4 (en) 2006-03-01
BR0212928A (pt) 2004-10-13
WO2003028754A1 (en) 2003-04-10
IL160882A0 (en) 2004-08-31
MXPA04002915A (es) 2004-07-05
CA2461596A1 (en) 2003-04-10
ZA200402231B (en) 2005-03-22
HUP0401659A3 (en) 2005-02-28
EP1435997A1 (en) 2004-07-14
JP2005508926A (ja) 2005-04-07
US20080213218A1 (en) 2008-09-04
HUP0401659A2 (hu) 2004-11-29
CN1561227A (zh) 2005-01-05

Similar Documents

Publication Publication Date Title
EE05442B1 (et) V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks
DE60215157D1 (de) Verwendungen von antiviralen nucleosid-derivaten zur herstellung eines medikaments zur behandlung von hepatitis c infektionen
IL245956A0 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
ATE315938T1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
ATE344253T1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
NO20031615D0 (no) Pyrazol-derivater for behandling av virus-sykdommer
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
EP1357940A4 (en) HEPATITIS? B? VIRUS THERAPY
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
NO20041855L (no) Fremgangsmate for behandling av hepatitt C-virusinfeksjon ved behandling av feilpasienter
NO20041685L (no) Fremgangsmate for behandling av hepatitt C-virusinfeksjon hos pasienter med manglende behandlingsrespons
EP1765330A4 (en) PYRANOINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DISEASE OR INFECTION CAUSED BY HEPATITIS C VIRUS
ZA200703157B (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
NO20022816L (no) Behandling av virale infeksjoner ved anvendelse av Levovirin
DE60124560D1 (de) Behandlung von angiogenesebezogenen krankheiten mit benzoyl phenylessigsäure derivaten
DE60006412D1 (de) Oxazinochinolone zur behandlung von viralen infektionen
IL161138A0 (en) Treatment of hepatitis b virus infection with human monoclonal antibodies
NO20032769D0 (no) Kombinasjonsmetode for behandling av virale infeksjoner
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
IL236510A0 (en) Use of one or more hbv antigens for the preparation of oral pharmaceutical compositions for treating a subject having an active hbv infection or hepatocellular carcinoma
NO20024325D0 (no) Rensede hepatitt C-viruskappeproteiner for diagnostisk og terapeutisk anvendelse
DE60114448D1 (de) Imidazolonderivate zur behandlung viraler krankheiten
NO20022253L (no) Middel til behandling av hepatitt C

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application